Occuity is in the process of designing and developing a range of handheld Optical non-contact Pachymeters, Pupillometers and Keratometers for use in both human and veterinary optometry.
Following years of research and based on our patented technology (nine granted patents, five pending and one further in draft), the company's mission is to develop and bring to market affordable, handheld devices capable of measuring ocular parameters that presently require contacting ultrasound devices at the lower price range or expensive optical desktop models at the higher end. Occuity believes they have the technology and are developing the partnerships required to produce devices capable of providing the measuring and non-contacting capabilities of the existing optical desktop devices at a price point more akin to the handheld contacting ultrasound devices. Occuity believes the nature and pricing of these new devices will prove disruptive to the current optometry market.
Click below for more details.
Handheld Optical non-contacting corneal thickness measurement
The first of Occuity's revolutionary optical handheld devices, the entry-level PM1 Pachymeter allows for a non-clinical operator to take a corneal thickness measurement quickly and easily.
Includes Pupillometer and Keratometer
The upgraded version of the PM1 will provide pachymetery alongside measurement sets required for pupillometry and keratometry.
Because our devices are both handheld and non-contacting this makes them ideal for use in the veterinary sector.
Once the devices have undergone CE approval it is planned that they will also undergo the necessary trials to be able to be used in veterinary environments.
This represents a significant yet completely untapped opportunity.
The Pachymeter Development
The Pachymeter has come a long way since our first prototype device.
2019 - The first pachymeter prototype (December tested the scanning optics and data collection but linked to a separate PC to process the data and supply power.
Q1 2020 - The next prototype miniaturized the technology from the first device, added in a camera and rear screen and moved to a self-contained, battery-powered version complete with its own processing power.
Q3 2020 - The production prototype is close to the final device and contains enhancements to the second device with a better camera, screen, processing, and connectivity options. This device is planned to undergo CE and FDA approval and will be used in the clinical trials in Q1 2022.